|
|
Vaccine Detail
|
G250 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: G250 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007566
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGEA9
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs.(NCIT_C53410)
|
| Host Response |
|
|
| References |
NCIT_C53410: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53410]
|
|
